2 assets in Serous Adenocarcinoma

Therapeutic assets addressing Serous Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Dostarlimab Serous Adenocarcinoma	University Health Network, Toronto	P2	CCC (53)
Niraparib Serous Adenocarcinoma	University Health Network, Toronto	P2	CCC (53)